Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2014-01-28 Interim / Quarterly Rep…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages 53.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated cash flow statements for the current quarter and year to date, payments to directors, financing facilities, reconciliation of cash, and compliance statements. The presence of quarterly financial data and cash flow statements indicates this is a comprehensive interim financial report for a period shorter than a full fiscal year. The document length is 6824 characters, which is sufficient to contain substantive financial data rather than just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2014
2014-01-28 English
Appendix 4C Cash Flow Report 31 December 2013 2 pages 51.2KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'Appendix 4C Quarterly Cash Flow Report 31 December 2013' and provides a summary of the company's quarterly cash flow for the quarter ended 31 December 2013. It includes specific financial figures such as cash balance, net operating cash flow, receipts from customers, and operating payments. The document is about a quarterly cash flow report, which is a type of interim or quarterly financial report. The length of the document (5679 characters) and the presence of substantive financial data and analysis confirm it is a financial report rather than a mere announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2014
2014-01-28 English
Change in substantial holding 2 pages 303.5KB
Regulatory Filings
2014-01-22 English
Executive change 2 pages 63.9KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 21 January 2014. It announces the retirement of Dr. Paul Tan from his role as Chief Science and Medical Officer and the interim appointment of Dr. Andrea Grant to assume those duties. The content focuses solely on an executive change and does not contain financial data, report attachments, or references to financial results or filings. There is no indication that this is a full report, earnings release, or any other financial document. The document fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2014-01-20 English
Withdrawal of NTCELL pre-clinical study 3 pages 279.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited regarding the withdrawal of a pre-clinical study publication and the placing on hold of a clinical trial phase. It discusses regulatory interactions, clinical trial status, and financial implications related to milestone payments. The document is an announcement of a specific event affecting the company's clinical development program rather than a full financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it provides substantive information about the withdrawal and trial hold. The content fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about clinical trial status and related corporate developments that do not fit other specific categories.
2013-12-18 English
Change of Director's Interest Notice 3 pages 73.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares and options acquired, dates of changes, and nature of the transactions. This is a clear report of personal share transactions by a company director. The document length is short and focused solely on director's dealings, with no financial statements or broader company information. Therefore, it fits the category of Director's Dealing (DIRS).
2013-12-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.